Ähnliche Pins
J&J Completes Its $1 Billion Acquisition of Firefly Bio
BESTÄTIGT87 % SICHERHEITvor 56 Tagen"NEW BRUNSWICK, NJ (July 29, 2026) - Johnson & Johnson (NYSE: JNJ[1][3]) today announced the successful completion of its acquisition of Firefly Bio, Inc. ... for $1 billion in cash"; the 8-K furnishing it gives "Date of report (Date of earliest event reported): July 29, 2026".Johnson & Johnson closed its $1 billion cash purchase of Firefly Bio, the South San Francisco biotech behind the Firelink degrader antibody conjugate platform for KRAS-driven and other hard-to-treat solid tumours.$1B0.68J&J Proposes $5.5 Billion Deal to Settle 76,000 Ovarian Cancer Talc Claims
BESTÄTIGT82 % SICHERHEITvor 58 TagenJ&J's release is datelined "New Brunswick, N.J. - JULY 27, 2026 - Johnson & Johnson (NYSE: JNJ[1]) ... today announced", and the copy filed as Exhibit 99.1 to its 8-K is marked "FOR RELEASE AT 6:15PM ET", 22:15 UTC in EDT.Johnson & Johnson announced a proposed resolution of its remaining ovarian talc litigation, about 76,000 claims, with a $5.5 billion commitment paid per claim - no more than $3 billion in 2027 and nothing more before 2028 - if at least 95% of claimants take part.$5.5B0.68DePuy Synthes trennt sich von Johnson & Johnson
GESCHÄTZT71 % SICHERHEITin 281 TagenDas 10-Q von J&J für das am 28. Juni 2026 endende Quartal strebt einen „Abschluss innerhalb von 18 bis 24 Monaten nach der ursprünglichen Ankündigung" vom 14. Oktober 2025 an (Mitte April bis Mitte Oktober 2027), und Finanzchef Joseph Wolk sagte im Juli, J&J sei „auf Kurs für eine Trennung Mitte 2027" (Bloomberg); „Mitte 2027" wird als Jahresmitte, also 1. Juli 2027, gelesen, was innerhalb dieses Zeitfensters liegt.[1]Das Orthopädiegeschäft von Johnson & Johnson soll als DePuy Synthes aus dem Konzern ausscheiden – per steuerfreiem Spin-off oder per Verkauf, wobei Apollo über rund 20 Milliarden Dollar verhandelt. J&J sieht sich auf Kurs für eine Trennung Mitte 2027.0.65J&J Announces Plan to Spin Off DePuy Synthes
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson…
BESTÄTIGT90 % SICHERHEITvor 344 TagenThe release is datelined "NEW BRUNSWICK, NJ, October 14, 2025 - Johnson & Johnson ... today announced the Company's intent to separate its Orthopaedics business"; it states no time of day (CNBC's[3] report was up at 6:29 a.m. EDT and J&J's X post at 6:40 a.m. EDT), so the pin is the all-day 14 October.Johnson & Johnson said it would separate its roughly $9.2 billion-a-year orthopaedics business into a standalone company called DePuy Synthes within 18 to 24 months, and named former Smith & Nephew chief Namal Nawana to run it.0.65J&J Q2 2026 Results: $25.3B Sales, 2026 Outlook Raised
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United States
BESTÄTIGT83 % SICHERHEITvor 70 TagenConfirmed by J&J's release dated "New Brunswick, N.J. (July 15, 2026)", which says it "will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time" (12:30 UTC; the edited transcript is stamped "JULY 15, 2026 / 12:30PM GMT").[1]Johnson & Johnson reported second-quarter sales of $25.3 billion, up 6.6%, and adjusted EPS of $2.90, and raised its 2026 outlook to about $101.1 billion in sales and $11.68 adjusted EPS at the midpoint.0.64J&J Picks Wilson, North Carolina for a Second 500-Job Drug Plant
BESTÄTIGT87 % SICHERHEITvor 257 TagenThe governor's release is dated "Friday, January 9, 2026" and begins "Today Governor Josh Stein announced Johnson & Johnson ... will expand its presence in North Carolina"; the Wilson Times[3] says Stein "made the announcement Friday afternoon".North Carolina Governor Josh Stein announced that Johnson & Johnson will build a second multibillion-dollar plant in Wilson, a drug product manufacturing facility for cancer and neurology medicines expected to create up to 500 jobs, beside the $2 billion biologics campus it is already building there.0.64J&J Third-Quarter 2026 Results and Investor Call
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United States
GEPLANT73 % SICHERHEITin 20 TagenScheduled by J&J's 31 August release: it "will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 13th to review third-quarter results" and "The press release will be available at approximately 6:45 a.m. (Eastern Time) the morning of the conference call"; 8:30 a.m. EDT is 12:30 UTC.[1]Johnson & Johnson releases its third-quarter 2026 results at about 6:45 a.m. Eastern on Tuesday 13 October and reviews them on an 8:30 a.m. investor call hosted by CEO Joaquin Duato and CFO Joseph Wolk.0.63Apollo in Talks to Buy J&J's DePuy Synthes for About $20 Billion
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United States
BESTÄTIGT82 % SICHERHEITvor 12 TagenThe disclosure is Bloomberg's report, dated "September 11, 2026" (Yahoo's[1][2][5] syndicated copy went up at 22:26 UTC and quotes Friday's closing share prices); Reuters' write-up the same evening says "Bloomberg News reported on Friday", and Quartz's 14 September story is a follow-up, so the pin is the all-day 11 September.Bloomberg reported that Apollo Global Management is in talks to buy DePuy Synthes, J&J's $9.3 billion-a-year orthopaedics unit, at a value close to $20 billion, with a deal possible within weeks though J&J could still spin the unit off instead.$20B0.61FDA Authorizes Abbott's Libre Duo Glucose-Ketone Sensor
BESTÄTIGT87 % SICHERHEITvor 29 TagenThe release is datelined "ABBOTT PARK, Ill., Aug. 25, 2026" and says Abbott "today announced U.S. Food and Drug Administration (FDA[2][3]) authorization of its Libre Duo 10 Day system"; the FDA's De Novo record gives the same decision date, 08/25/2026.The FDA authorized Abbott's Libre Duo 10 Day, the first wearable to continuously track both glucose and ketones, which alerts people with diabetes aged 2 and older to rising ketones before diabetic ketoacidosis.0.59Lilly Agrees to Acquire Centessa for Up to $7.8 Billion
BESTÄTIGT87 % SICHERHEITvor 176 TagenThe joint release is datelined "INDIANAPOLIS and BOSTON and LONDON, March 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Centessa".[1]Lilly agrees to buy Centessa Pharmaceuticals, maker of the orexin agonist cleminorexton for narcolepsy, for $38 a share in cash (about $6.3 billion) plus a CVR worth up to $1.5 billion more; the deal closed on 24 June 2026.$7.8B0.59J&J Enterprise Business Review (Investor Day)
GEPLANT85 % SICHERHEITin 76 TagenJ&J set the date itself: CFO Joseph Wolk said on the 15 July Q2 call "We look forward to sharing more on strategy, growth catalysts and a longer-term outlook at our Enterprise business review on December 8", and the source[1] reports he "expects to present stronger growth expectations at its Dec. 8 investor day"; no time or venue has been announced, so the pin sits at J&J's headquarters as an all-day date.Johnson & Johnson holds its first enterprise business review since December 2023, where CFO Joseph Wolk says it will set out growth above its 5% to 7% long-term target, with a clear line of sight to double digits by the end of the decade.0.59US and Taiwan Sign a $250 Billion Chip Investment Deal
BESTÄTIGT86 % SICHERHEITvor 251 TagenCNBC[1], published 15 January 2026: 'The U.S. and Taiwan have reached a trade agreement ... the Department of Commerce announced Thursday'; USTR's[2] February fact sheet dates the 'Memorandum of Understanding signed by AIT and TECRO on January 15, 2026'. No signing time is given, so it is an all-day date.A memorandum signed in Washington commits Taiwanese chipmakers such as TSMC to at least $250 billion of new US investment plus $250 billion in Taiwan credit guarantees, in return for a 15% tariff cap and Section 232 chip-tariff exemptions for companies building US fabs.0.59
